Publicaciones en colaboración con investigadores/as de Hospital Universitari Germans Trias i Pujol (16)

2021

  1. Bovine peripheral blood MSCs chemotax towards inflammation and embryo implantation stimuli

    Journal of Cellular Physiology, Vol. 236, Núm. 2, pp. 1054-1067

2020

  1. Oral fosfomycin for the treatment of lower urinary tract infections among kidney transplant recipients—Results of a Spanish multicenter cohort

    American Journal of Transplantation, Vol. 20, Núm. 2, pp. 451-462

2019

  1. Rationale and Study Design for an Individualized Perioperative Open Lung Ventilatory Strategy in Patients on One-Lung Ventilation (iPROVE-OLV)

    Journal of Cardiothoracic and Vascular Anesthesia, Vol. 33, Núm. 9, pp. 2492-2502

2018

  1. Immunocompromised patients with acute respiratory distress syndrome: Secondary analysis of the LUNG SAFE database

    Critical Care, Vol. 22, Núm. 1

  2. Impact of co-infection by hepatitis C virus on immunological and virological response to antiretroviral therapy in HIV-positive patients

    Medicine (United States), Vol. 97, Núm. 38

  3. Individualised perioperative open-lung approach versus standard protective ventilation in abdominal surgery (iPROVE): a randomised controlled trial

    The Lancet Respiratory Medicine, Vol. 6, Núm. 3, pp. 193-203

  4. Low-level viremia is associated with clinical progression in HIV-infected patients receiving antiretroviral treatment

    Journal of Acquired Immune Deficiency Syndromes, Vol. 78, Núm. 3, pp. 329-337

2017

  1. Rationale and study design for an individualised perioperative open-lung ventilatory strategy with a high versus conventional inspiratory oxygen fraction (iPROVE-O2) and its effects on surgical site infection: Study protocol for a randomised controlled trial

    BMJ Open, Vol. 7, Núm. 7

  2. Simplification to dual therapy (atazanavir/ritonavir1lamivudine) versus standard triple therapy [atazanavir/ritonavir1two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study)

    Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 1, pp. 246-253

2015

  1. Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial

    The Lancet Infectious Diseases, Vol. 15, Núm. 7, pp. 775-784

  2. Novel blaROB-1-bearing plasmid conferring resistance to β-lactams in Haemophilus parasuis isolates from healthy weaning pigs

    Applied and Environmental Microbiology, Vol. 81, Núm. 9, pp. 3255-3267

  3. Rationale and study design for an individualized perioperative open lung ventilatory strategy (iPROVE): Study protocol for a randomized controlled trial

    Trials, Vol. 16, Núm. 1

2013

  1. Generation of HIV-1 Gag VLPs by transient transfection of HEK 293 suspension cell cultures using an optimized animal-derived component free medium

    Journal of Biotechnology, Vol. 166, Núm. 4, pp. 152-165

  2. Increase in gonorrhoea among very young adolescents, Catalonia, Spain, January 2012 to June 2013

    Eurosurveillance, Vol. 18, Núm. 33

2007

  1. Evolution of the antimicrobial resistance of Pseudomonas aeruginosa in Spain: Second National Study (2003)

    Revista Espanola de Quimioterapia, Vol. 20, Núm. 2, pp. 222-229

2006

  1. Rosiglitazone and 15-deoxy-Δ12,14-prostaglandin J 2 cause potent neuroprotection after experimental stroke through noncompletely overlapping mechanisms

    Journal of Cerebral Blood Flow and Metabolism, Vol. 26, Núm. 2, pp. 218-229